Astrazeneca (AZN) Income from Non-Controlling Interests (2009 - 2026)

Astrazeneca's Income from Non-Controlling Interests history runs 18 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests fell 98.91% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $11.0 million (down 88.04% YoY), while the FY2025 annual figure was $52.0 million, down 38.82% from the prior year.
• Income from Non-Controlling Interests was $1.0 million for Q1 2026 at Astrazeneca, down from $9.0 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $92.0 million in Q1 2025 to a low of -$1.0 million in Q4 2023.
• Historically, Income from Non-Controlling Interests has averaged $19.4 million across 5 years, with a median of $2.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests sank 200.0% in 2023, then surged 9100.0% in 2025.
• A 5-year view of Income from Non-Controlling Interests shows it stood at $1.0 million in 2022, then tumbled by 200.0% to -$1.0 million in 2023, then changed by 0.0% to -$1.0 million in 2024, then surged by 1000.0% to $9.0 million in 2025, then sank by 88.89% to $1.0 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at $1.0 million (Q1 2026), $9.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.